Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-(2,5-dideoxy-5-pyrrolidin-1-yl-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione
- Development stage
- Preclinical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
This compound is a synthetic nucleoside analog belonging to the class of 2',5'-dideoxyribonucleosides. Its structure features a pyrrolidine ring attached to a modified pentose sugar and a methylated pyrimidine base. It is classified as an experimental small molecule and has been investigated primarily for antiviral activity. Patent literature suggests its potential use in the treatment of liver disorders such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections[4]. The mechanism likely involves interference with viral replication by acting as an antimetabolite or chain terminator during nucleic acid synthesis—a common mode of action for nucleoside analogs[4]. However, there are no approved indications or marketed products containing this compound.
- Other names
- 1-[2,5-Dideoxy-5-(1-pyrrolidinyl)-β-L-erythro-pentofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidinedione1-[2,5-Didesoxy-5-(1-pyrrolidinyl)-β-L-erythro-pentofuranosyl]-5-methyl-2,4(1H,3H)-pyrimidindion2,4(1H,3H)-Pyrimidinedione, 1-[2,5-dideoxy-5-(1-pyrrolidinyl)-β-L-erythro-pentofuranosyl]-5-methyl-
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on 1-(2,5-dideoxy-5-pyrrolidin-1-yl-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-(2,5-dideoxy-5-pyrrolidin-1-yl-beta-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione.